Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination with Vincristine and Temozolomide in Adolescents and Young Adults with Relapsed or Refractory Sarcomas

Next Previous
Trial Profile

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination with Vincristine and Temozolomide in Adolescents and Young Adults with Relapsed or Refractory Sarcomas

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PEG [SN22]4 (Primary) ; Temozolomide (Primary) ; Vincristine (Primary) ; Filgrastim; Pegfilgrastim
  • Indications Ewing's sarcoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 13 Feb 2025 Status changed from not yet recruiting to recruiting.
  • 22 Jan 2025 Planned initiation date changed from 1 Dec 2024 to 1 Jan 2025.
  • 03 Dec 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top